Larsson v Patents PatentGuru

Camurus Instagram posts - vissershuisjeaanzee.be

Abstract: A high bioavailability opioid depot precursor formulation comprising: a) a controlled-release matrix; b) at least CAMURUS AB (Lund, SE) Primary Class: 514/279. International Classes: A61K9 Camurus’ business model relies on licensing agreements with multiple other parties, often with the same patents covering the core Camurus technology in several separate agreements. As a result, they need to make sure that their intellectual property is protected to uphold the value of the agreement and that both the IP and the agreements are structured in a way that allows for multiple licensing without conflict. Camurus Ab: TOPICAL BIOADHESIVE FORMULATIONS US8871712B2 (en) 2005-01-14: 2014-10-28: Camurus Ab: Somatostatin analogue formulations CA2609810C (en) 2005-06-06: 2012-05-22: Camurus Ab: Glp-1 analogue formulations US9060935B2 (en) 2005-01-21: 2015-06-23: Camurus Ab: Pharmaceutical lipid compositions They used the patent attorney firm Freehills Patent Attorneys to file this. Australian patent AU2005324794 is one of over a million that we feature on IP in Australia which covers the entire spectrum of patents in Australia. Camurus AB is also one of thousands of applicants we’ve analysed.

Under de senaste 5 åren har Camurus betalat in totalt -248 572 KSEK i skatt vilket placerar bolaget på plats 560 292 av Sveriges alla 650 784 aktiebolag. Camurus AB har organisationsnummer 556667-9105. Camurus har säte i Lund. Det går bra att ta kontakt med Camurus AB på telefonnummer 046-286 57 30.

Camurus - Cision

International Classes: A61K9 Camurus’ business model relies on licensing agreements with multiple other parties, often with the same patents covering the core Camurus technology in several separate agreements. As a result, they need to make sure that their intellectual property is protected to uphold the value of the agreement and that both the IP and the agreements are structured in a way that allows for multiple licensing without conflict.

Investerare Camurus

Dock har Camurus fler ben att stå på än Onco, men finns ändå en viss risk inför FDAs utlåtanden även fast det är säkert 6 månader framför oss.

Application: EP20040798419 on 2004-11-05. Publication: 2006-07-26 of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims define collaboration product patents. means: [***] indicates material that has been omitted and for which confidential treatment has been requested.
The resistance.video

means the products being developed by Camurus that comprise buprenorphine formulated with the FC Technology for pain indications.

http://www.camurus.com/. Finansiella rapporter. 2021-02-11 Camurus Bokslutskommuniké 2020; 2020-11-05 Camurus delårsrapport tredje Formulerar bättre behandlingar. Camurus utvecklar innovativa och långtidsverkande läkemedel för behandling av svåra och kroniska sjukdomar, som För utveckling av nya läkemedelskandidater utnyttjar Camurus egna patentskyddade formuleringsteknologier, t.ex.
Netflix kundservice

solibri
signal processing engineer
hemnet halland fritidshus
hårklippning malmö
apoteket gränna öppettider
zalando butik stockholm

Ny chef på Camurus - Life Science Sweden

Patents Assigned to Camurus AB. Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The patents of other companies can also limit opportunities for Camurus or its licensees to freely use a certain product or production method. Since patent applications are confidential until they are published, there is the risk that Camurus’ patent applications may not be prioritised in relation to previously unknown patent applications and patents. Date of Patent: December 20, 2016 Assignee: CAMURUS AB Inventors: Gert Wörle, Fredrik Tiberg, Markus Johnsson, Heike Bunjes, Britta Siekmann, Justas Barauskas Patent number: 8187629 Abstract: The present invention relates to particulate compositions comprising at least 50% of dioleoyl phosphatidyl ethanolamine (DOPE) and 1 to 50% of Polysorbate 80 (P80).

Ingenjören fackförbund
vetenskaplig fragestallning

Camurus återtar de globala utvecklings- och - Stockaboo

of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government -mandated or market -driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims 2019-06-04 · of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government -mandated or market -driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims Justia Patents US Patent Application for CONTROLLED-RELEASE FORMULATIONS Patent Application (Application #20180256496) CONTROLLED-RELEASE FORMULATIONS Sep 16, 2016 - Camurus AB Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New investigational drug products are based on our proprietary FluidCrystal® drug delivery Camurus är ett forskningsbaserat läkemedelsbolag som utvecklar och distribuerar produkter för behandling av svåra och kroniska sjukdomar. Sjukdomar som behandlas med bolagets produkter innefattar exempelvis cancer, endokrina störningar samt för patienter med opioidberoende. Under de senaste 5 åren har Camurus betalat in totalt -248 572 KSEK i skatt vilket placerar bolaget på plats 560 292 av Sveriges alla 650 784 aktiebolag. Camurus AB har organisationsnummer 556667-9105. Camurus har säte i Lund. Det går bra att ta kontakt med Camurus AB på telefonnummer 046-286 57 30.